Renal cell carcinoma (RCC)

Overview

Renal cell carcinoma (RCC) is the most common renal tumour and accounts for approximately 90% of all renal malignancies.¹ Despite advances in screening, 25–30% of patients with RCC present with metastatic RCC (mRCC) at the time of diagnosis² and 20–30% of patients undergoing nephrectomy will experience relapse and develop metastases.^1,3

For these patients with mRCC, outcomes are generally poor and the incidence of RCC and mRCC imposes a serious worldwide epidemiological burden.²

This information has been provided with the kind permission of Börje Ljungberg

References:
1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. 2009. Available at: http:/anti-infectives/Paris-Event/Live-Webcast.cfmwww.nccn.org/professionals/physician_gls/f_guidelines.asp
2. Gupta K, Miller JD, Li JZ et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34:193–205.
3. Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 2008;15:3954–3966.